Palabras clave
Inhibidores de las Cinasas Janus
Productos Biológicos
Cómo citar
Resumen
La dermatitis atópica (DA) es una enfermedad inflamatoria crónica que afecta predominantemente a niños y adolescentes, con un impacto significativo en su calidad de vida y bienestar psicosocial.
La mayoría de los pacientes con DA presentan formas leves y mejoran con medidas higiénicas y tratamientos tópicos, pero 5%-20% son moderadas o severas y en estos casos se requieren otras intervenciones. Hasta hace unos años los inmunosupresores, como corticoides sistémicos, ciclosporina, azatioprina, micofenolato de mofetilo y metotrexato eran las únicas opciones de tratamiento sistémico disponibles para pacientes con DA moderada o severa, pero actualmente existen otras opciones terapéuticas para estos pacientes, como son los fármacos biológicos o inhibidores JAK, entre otros. Este artículo tiene como objetivo revisar los avances recientes en el tratamiento de la DA, centrándose específicamente en estos nuevos fármacos biológicos e inhibidores JAK aprobados en el tratamiento de la DA moderada a severa en niños y adolescentes, con especial atención en los fármacos utilizados y disponibles en Uruguay.
Citas
Esaki H, Brunner P, Renert Y, Czarnowicki T, Huynh T, Tran G, et al. Early-onset pediatric atopic dermatitis is TH2 but also TH17 polarized in skin. J Allergy Clin Immunol 2016; 138(6):1639-51. doi: 10.1016/j.jaci.2016.07.013.
Faye O, Flohr C, Kabashima K, Ma L, Paller A, Rapelanoro F, et al. Atopic dermatitis: A global health perspective. J Eur Acad Dermatol Venereol 2024; 38(5):801-11. doi: 10.1111/jdv.19723.
Drucker A, Lam M, Prieto D, Malek R, Ellis A, Yiu Z, et al. Systemic immunomodulatory treatments for atopic dermatitis: living systematic review and network meta-analysis update. JAMA Dermatol 2024; 160(9):936-44. doi: 10.1001/jamadermatol.2024.2192.
Chu A, Wong M, Rayner D, Guyatt G, Díaz J, Ceccacci R, et al. Systemic treatments for atopic dermatitis (eczema): Systematic review and network meta-analysis of randomized trials. J Allergy Clin Immunol 2023; 152(6):1470-92. doi: 10.1016/j.jaci.2023.08.029.
García C, Cubiró X, Puig L. Inhibidores de JAK: usos en dermatología. Parte 1: generalidades, aplicaciones en vitíligo y en alopecia areata. Actas Dermosifiliogr 2021; 112(3):215-23. doi:10.1016/j.ad.2020.12.003.
Yoon S, Kim K, Shin K, Kim H, Kim B, Kim M, et al. The safety of systemic Janus kinase inhibitors in atopic dermatitis: a systematic review and meta-analysis of randomized controlled trials. J Eur Acad Dermatol Venereol 2024; 38(1):52-61. doi: 10.1111/jdv.19426.
GBD 2021 Asthma and Allergic Diseases Collaborators. Global, regional, and national burden of asthma and atopic dermatitis, 1990-2021, and projections to 2050: a systematic analysis of the Global Burden of Disease Study 2021. Lancet Respir Med 2025; 13(5):425-46. doi: 10.1016/S2213-2600(25)00003-7.
Wollenberg A, Kinberger M, Arents B, Aszodi N, Avila G, Barbarot S, et al. European guideline (EuroGuiDerm) on atopic eczema: part I - systemic therapy. J Eur Acad Dermatol Venereol 2022; 36(9):1409-31. doi: 10.1111/jdv.18345.
Wollenberg A, Kinberger M, Arents B, Aszodi N, Avila G, Barbarot S, et al. European guideline (EuroGuiDerm) on atopic eczema - part II: non-systemictreatments and treatment recommendations for special AE patient populations. J Eur Acad Dermatol Venereol 2022; 36(11):1904-26. doi: 10.1111/jdv.18429.
Wollenberg A, Kinberger M, Arents B, Aszodi N, Barbarot S, Bieber T, et al. First update of the living European guideline (EuroGuiDerm) on atopic eczema. J Eur Acad Dermatol Venereol 2023; 37(11):e1283-7. doi: 10.1111/jdv.19269.
Deva M, Netting M, Weidinger J, Brand R, Loh R, Vale S. A systematic review of guidelines for the management of atopic dermatitis in children. World Allergy Organ J 2024; 17(12):100989. doi: 10.1016/j.waojou.2024.100989.
Huang L, Zhao D, Lin H, Zheng H, Li X, Chen L, et al. Efficacy and safety of upadacitinib in the treatment of moderate-to-severe atopic dermatitis in adolescents: A systematic review and meta-analysis of randomized controlled trials. Medicine (Baltimore) 2024; 103(38):e39826. doi: 10.1097/MD.0000000000039826.
Silverberg J, Bunick C, Hong H, Mendes P, Stein L, Costanzo A, et al. Efficacy and safety of upadacitinib versus dupilumab in adults and adolescents with moderate-to-severe atopic dermatitis: week 16 results of an open-label randomized efficacy assessor-blinded head-to-head phase IIIb/IV study (Level Up). Br J Dermatol 2024; 192(1):36-45. doi: 10.1093/bjd/ljae404.
Paller A, Mendes P, Siegfried E, Eichenfield L, Soong W, Prajapati V, et al. Upadacitinib in adolescents with moderate to severe atopic dermatitis: analysis of 3 phase 3 randomized clinical trials through 76 weeks. JAMA Dermatol 2024; 160(12):1304-13. doi: 10.1001/jamadermatol.2024.3696.
Cork M, Thaçi D, Eichenfield L, Arkwright P, Sun X, Chen Z, et al. Dupilumab provides favourable long-term safety and efficacy in children aged ≥ 6 to < 12 years with uncontrolled severe atopic dermatitis: results from an open-label phase IIa study and subsequent phase III open-label extDermatol 2021; 184(5):857-70. doi: 10.1111/bjd.19460.
Paller A, Siegfried E, Simpson E, Cork M, Sidbury R, Chen I, et al. Dupilumab safety and efficacy up to 1 year in children aged 6 months to 5 years with atopic dermatitis: results from a phase 3 open-label extension study. Am J Clin Dermatol 2024; 25(4):655-68. doi: 10.1007/s40257-024-00859-y.
Paller A, Flohr C, Cork M, Bewley A, Blauvelt A, Hong H, et al. Efficacy and safety of tralokinumab in adolescents with moderate to severe atopic dermatitis: the phase 3 ECZTRA 6 randomized clinical trial. JAMA Dermatol 2023; 159(6):596-605. doi: 10.1001/jamadermatol.2023.0627.
Reich K, Silverberg J, Papp K, Deleuran M, Katoh N, Strober B, et al. Abrocitinib efficacy and safety in patients with moderate-to-severe atopic dermatitis: Results from phase 3 studies, including the long-term extension JADE EXTEND study. J Eur Acad Dermatol Venereol 2023; 37(10):2056-66. doi: 10.1111/jdv.19280.
Torrelo A, Rewerska B, Galimberti M, Paller A, Yang C, Prakash A, et al. Efficacy and safety of baricitinib in combination with topical corticosteroids in paediatric patients with moderate-to-severe atopic dermatitis with an inadequate response to topical corticosteroids: results from a phase III, randomized, double-blind, placebo-controlled study (BREEZE-AD PEDS). Br J Dermatol 2023; 189(1):23-32. doi: 10.1093/bjd/ljad096.
Zheng Y, Ding R, Bu J. Effectiveness and safety of systemic therapy for moderate-to-severe atopic dermatitis in children and adolescent patients: a systematic review. Front Immunol 2024; 15:1367099. doi: 10.3389/fimmu.2024.1367099.
Esta obra está bajo una licencia internacional Creative Commons Atribución 4.0.
Derechos de autor 2026 María José González , Patricia Kutscher, Agustina Acosta